MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Inicio・Lista de Acciones・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Abierto

SectorSanidad

497.65 0.21

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

491.46

Máximo

504.12

Métricas clave
By Trading Economics
Ingresos	-72M -114M
Ventas	74M 287M
Margen de beneficios	-39.75
Empleados	528
EBITDA	-68M -106M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+30.79% upside

Dividendos
By Dow Jones
Próximas Ganancias	25 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.2B 11B
Apertura anterior	497.44
Cierre anterior	497.65

Noticias sobre sentimiento de mercado

By Acuity

39%

61%

136 / 360 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

263.2 / 277.1 Soporte y Resistencia

Madrigal Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 ene 2026, 23:49 UTC

Principales Movimientos del Mercado

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 ene 2026, 21:12 UTC

Principales Movimientos del Mercado

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 ene 2026, 21:00 UTC

Adquisiciones, fusiones, absorciones

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 ene 2026, 20:29 UTC

Principales Movimientos del Mercado

Chip Makers Gain After Trump Calls Off European Tariffs

21 ene 2026, 20:04 UTC

Principales Movimientos del Mercado

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 ene 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 ene 2026, 23:34 UTC

Charlas de Mercado

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 ene 2026, 22:39 UTC

Ganancias

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 ene 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

21 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

21 ene 2026, 21:35 UTC

Adquisiciones, fusiones, absorciones

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 ene 2026, 21:19 UTC

Ganancias

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 ene 2026, 20:45 UTC

Adquisiciones, fusiones, absorciones

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 ene 2026, 20:36 UTC

Charlas de Mercado

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 ene 2026, 20:31 UTC

Charlas de Mercado

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 ene 2026, 20:27 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 ene 2026, 20:27 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 ene 2026, 20:27 UTC

Charlas de Mercado

Was It a 'TACO' Event? -- Market Talk

21 ene 2026, 20:26 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 ene 2026, 20:23 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 ene 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 ene 2026, 20:19 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse Group Agrees to Buy Allfunds

21 ene 2026, 20:08 UTC

Ganancias

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 ene 2026, 20:03 UTC

Charlas de Mercado

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 ene 2026, 19:51 UTC

Charlas de Mercado

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 ene 2026, 19:43 UTC

Charlas de Mercado

U.S. Ethanol Production Expected to Slip -- Market Talk

21 ene 2026, 19:31 UTC

Charlas de Mercado

Gold Settles at Fresh All-Time High -- Market Talk

21 ene 2026, 19:24 UTC

Ganancias

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 ene 2026, 19:10 UTC

Charlas de Mercado

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 ene 2026, 18:57 UTC

Charlas de Mercado

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Comparación entre iguales

Cambio de precio

Madrigal Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

30.79% repunte

Estimación a 12 Meses

Media 660.44 USD 30.79%

Máximo 900 USD

Mínimo 533 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Madrigal Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para Madrigal Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

263.2 / 277.1Soporte y Resistencia

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

136 / 360 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.